Hanmi Pharm
| Market cap | ₩6.5T |
| PE ratio | 29.75 |
| Forward PE | 24.56 |
| PB ratio | 4.56 |
| EPS | ₩16,942 |
| Dividend (yield) | ₩2,000 (0.40%) |
| Analysts (1–5) | 4.00 · Buy |
| Price target | ₩668,333 (+32.08%) |
| Volume | 54,265 |
| Trading value | ₩27.2B |
| Day’s range | ₩492,500 – ₩507,000 |
| 52-week range | ₩302,000 – ₩647,000 |
| Foreign ownership KR | 12.78% |
| Foreign net buy (Oct 2) KR | +377 sh |
| Book value / share | ₩110,632 |
| Founded | 2010 |
Close (KRW) Foreign ownership, % of shares (right axis)
Foreign, institutional and retail net buying KR data
Shares by trading day; positive means net buying. Korea publishes investor-type flows for every stock — global sites such as Yahoo or StockAnalysis do not show them.
| Date | Close | Foreigners | Institutions | Retail | Foreign ownership |
|---|---|---|---|---|---|
| Oct 2 | ₩506,000 | +377 | +2,111 | −2,259 | 12.79% |
| Oct 1 | ₩497,500 | −644 | +1,539 | −1,328 | 12.79% |
| Sep 30 | ₩499,000 | +9,466 | +499 | −10,142 | 12.77% |
| Sep 29 | ₩507,000 | +4,534 | −2,137 | −2,046 | 12.68% |
| Sep 28 | ₩504,000 | −6,294 | −3,118 | +11,208 | 12.63% |
Financials
Annual, consolidated where available, KRW. Columns ending in E are analyst consensus estimates. Source: company filings (DART) via Naver Finance.
| Item | FY2023 | FY2024 | FY2025 | FY2026E |
|---|---|---|---|---|
| Revenue | ₩1.5T | ₩1.5T | ₩1.5T | ₩1.8T |
| Operating income | ₩220.7B | ₩216.2B | ₩257.8B | ₩366.5B |
| Net income | ₩165.4B | ₩140.4B | ₩187.1B | ₩284.5B |
| Operating margin | 14.80% | 14.46% | 16.66% | 20.83% |
| Return on equity | 16.00% | 11.89% | 14.52% | 19.06% |
| Debt-to-equity | 72.57% | 62.87% | 50.23% | – |
| EPS | ₩11,415 | ₩9,470 | ₩13,235 | ₩20,521 |
| Dividend per share | ₩490 | ₩1,250 | ₩2,000 | ₩1,932 |
Peers
| Samsung Biologics 207940 | ₩1,354,000 | −4.51% |
| Celltrion 068270 | ₩182,600 | −0.54% |
| Samsung Epis Holdings 0126Z0 | ₩365,000 | −2.28% |
| SK Biopharmaceuticals 326030 | ₩75,800 | −1.17% |
| Yuhan 000100 | ₩74,100 | −0.94% |
| Sam Chun Dang Pharm 000250 | ₩207,000 | +3.81% |
About
Hanmi Pharm makes and sells pharmaceuticals and was created in 2010 when its parent spun off its drug manufacturing and sales business. It has 5 consolidated subsidiaries, 1 in Korea and 4 overseas, grouped into pharmaceuticals, active pharmaceutical ingredients and overseas pharmaceuticals. It recently made Aptose Biosciences Inc., a listed overseas company, a consolidated subsidiary after acquiring additional shares.
Hanmi Pharm. Co., Ltd. is listed on the KOSPI market of the Korea Exchange under the ticker 128940. Industry: Pharmaceuticals.
Direct KRX access through a global broker, a US-listed ADR where one exists, or a Korea ETF — compared in our guide.
Data: Korea Exchange closing prices, investor flows and foreign ownership via Naver Finance; company information from DART (Financial Supervisory Service). Updated after each Korean market close; ratios and flows as of Oct 2, 2026. Delayed data, not investment advice.